http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#Head http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#assertion http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#provenance http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#pubinfo http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#assertion http://purl.obolibrary.org/obo/DOID_1040 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_1040 http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01073 http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association http://www.w3.org/2000/01/rdf-schema#label fludarabine phosphate injection is a nucleotide metabolic inhibitor indicated for the treatment of adult patients with b cell chronic lymphocytic leukemia cll who have not responded to or whose disease has progressed during treatment with at least one standard alkylating agent containing regimen benefit in treatment naive or non refractory cll patients is not established 1 1 important limitations fludarabine phosphate should not be used in patients with severe renal impairment creatinine clearance less than 3 ml min 1 73 m 2 5 7 fludarabine phosphate injection is indicated for the treatment of adult patients with b cell chronic lymphocytic leukemia cll who have not responded to or whose disease has progressed during treatment with at least one standard alkylating agent containing regimen the safety and effectiveness of fludarabine phosphate injection in previously untreated or non refractory patients with cll have not been established fludarabine phosphate injection should not be used in patients with severe renal impairment creatinine clearance less than 3 ml min 1 73 m 2 see warnings and precautions 5 7 http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01073 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#provenance http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#pubinfo http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#sig http://purl.org/nanopub/x/hasSignature YeU/DW6PY+UXoYcegbmX8nhXb4s9oeKYCNLRVlk+sQgQHEJocWTwODcOxEDbjjfYRlfKfxBrBcI9z/YiylcS96HD1spRUxAYx5MaqJgiQ0atdwkFPw/nqbYs+BFezqfjhHXrc98YW8ttngnzmwsVGzszblcJKP7zUUR/e3MLOWY= http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8 http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8 http://purl.org/dc/terms/created 2021-06-13T14:13:05.574+02:00 http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RATmOzTYudHzJrGPgN6p4gqiRSRXh6Lg-GXhzdIMkF5V8 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs